Please login to the form below
Phillip Frost to remain chair of Teva Pharmaceutical
Re-elected by board for at least three more years
Dr Phillip Frost has been re-elected as chair of Teva Pharmaceutical.
The Israel-based firm's board of directors unanimously voted for Dr Frost to remain in the position for at least three more years, subject to shareholder approval.
He has served as chair since March 2010, having previously been vice chair from January 2006.
Prior to his time at Teva, he was chair and CEO of IVAX Xorporate from 1987 to 2006.
The board's vice chair, Professor Moshe Many, said: “Dr Phillip Frost has the Board's full support. We would continue to benefit from his vision and guidance.
“We look forward to the progress of the company under the governance of the Board and the leadership of Teva's President and CEO Dr. Jeremy Levin.”
Dr Frost's continuation provides Teva with some stability as former senior vice president of strategy at Bristol-Myers Squibb, Jeremy Levin, begins his tenure as the company's CEO and president.
The company has also recently appointed genetics expert Dr Michael Hayden as its first president of global R&D and chief scientific officer.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- EU “still interested” in Valneva COVID vaccine despite UK snub
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- US demand for COVID-19 antibody treatments rising fast
- David Hunt launches independent agency The Considered
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- Robust Review: COVID19 Assessment
- Market Access Transformation (MAT) Secures First Institutional Funding Led by Silversmith Capital Partners
- IBD Registry wins Communiqué award for COVID-19 tool
- Havas Life Medicom named Agency Digital Team and leads agency wins at PM Digital Awards
- New data for Tecentriq in early-stage lung cancer
- David Hunt launches independent agency The Considered
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- WHO to test three more potential COVID-19 treatments
- UK announces COVID boosters for a “bumpy winter” ahead
- Assessing the value of interim analyses in clinical trials
PMHub
Research Partnership
We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
